The U.S. Food and Drug Administration cited Cecil-based Mylan Inc. for “significant violations” of manufacturing regulations at its generic drug plant in Puerto Rico, according to a warning letter released by the agency Tuesday. The letter, sent to Mylan Chairman and CEO Robert Coury, was issued Oct. 13 after an inspection at the plant conducted in January and February. During the inspection, “we identified significant violations of current good manufacturing practice regulations,” the warning letter stated.
